Navigation Links
"From Survive to Thrive" campaign seeks to enhance access to lifesaving donor milk in Neonatal Intensive Care Units in 2014
Date:11/22/2013

0;
More information about the "From Survive to Thrive" campaign will be made available as Medolac makes progress towards fulfilling its objective in 2014.   

About Medolac:

Our vision is to provide human milk based therapies to critically ill babies and children on a global basis by applying proprietary biopharmaceutical processing methods that preserve the immune components in human milk while providing the safest, highest quality human milk formulations available to babies in need.    Medolac Laboratories is a Delaware registered, public benefit corporation (Neolac Inc. dba Medolac) headquartered at Lake Oswego, Oregon in the Pacific Northwest of the United States. 

Media Contact: Yvonne Arroyo, Medolac Laboratories, 8665997740, Media@medolac.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Medolac Laboratories
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. What Hospitals Must Do to Thrive -- Not Just Survive -- on Medicare Margins
2. Medtech companies urged to evolve business model to survive
3. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
4. UV Flu Technologies to Commence a National TV Advertising Campaign
5. Research Triangle Region Debuts Talent Attraction Campaign at BIO 2012
6. Mandy Moore Campaigns for Clean Water, GreenBeanBuddy Encourages Mothers to Help Through the Use of Green Cleaning Products
7. New "GMO Inside" Campaign Denounces Corporate Disinformation Campaign That Defeated Californias Prop 37
8. Adult Stem Cell Therapy Breakthrough Leads to Crowd Funding Campaign on Indiegogo.com for Centagen, Inc.
9. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
10. Texas Fertility Center ‘March Dadness’ Campaign Focuses on the Odds of Beating Male Infertility
11. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... In terms of value, aluminium ... production volume reached close to 1.84 million tonnes in the same year. As ... of the region’s total aluminium hydroxide production; the country’s aluminium hydroxide production posted ...
(Date:7/28/2015)... 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) or ... today announced that its stockholders approved an increase in ... the Company from 1,000,000,000 to 2,500,000,000 at its Special ... the Law Offices of Nixon Peabody LLP in Midtown ... were 480,655,929 shares of common stock represented either by ...
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that it has granted to German life sciences ... development and commercialization of biotechnology (collectively, the "Optionee"), ... oral allogenic tumor vaccine technology (the "Technology"), including ... cancer which is ready to enter a Phase ...
(Date:7/27/2015)... and FRANKLIN, Tenn. ... a privately-owned  premier provider of health care services ... in the U.S., today announced that its parent ... signed a definitive agreement with Medical Properties Trust, ... acquisition of Capella for $900 million in cash.  The transaction ...
Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5
... FRANCISCO , Jan. 13 Today, endpoint ( ... users to design and deploy clinical trial IRT systems in ... Leveraging a background of more than 12 years designing Integrated ... designed PULSE to balance speed of deployment with flawless quality. ...
... ROCHESTER, N.Y. , Jan. 12 After a decade of ... decelerated and may have even fallen when adjusted for inflation.  That is ... the American Medical Association .   , "The era of rapid expansion ... Ray Dorsey , M.D. , a neurologist at the ...
... , ... Institute announces twenty-four exhibitors to showcase new products at the 17th Molecular Medicine Tri-Conference, ... Molecular Medicine Tri-Conference is the predominant event on the west coast focused on integrating ... ...
Cached Biology Technology:endpoint Introduces First Fully Configurable IRT System 2Study: Era of Rapid Growth in Biomedical Research Over 2Study: Era of Rapid Growth in Biomedical Research Over 3Study: Era of Rapid Growth in Biomedical Research Over 4Study: Era of Rapid Growth in Biomedical Research Over 5Study: Era of Rapid Growth in Biomedical Research Over 6A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 2A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 3A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 4
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... genetic and geographic data of the H5N1 avian flu ... They found that multiple strains of the virus originated ... many of the migration routes through which the strains ... strains develop and migrate, health officials can better limit ...
... hold a key to defeating another implacable foe: HIV. ... a drastically weakened rabies virus to ferry HIV-related proteins ... disease. The early evidence shows that the vaccine ?which ... , Reporting April 1, 2007 in the Journal of ...
... squeaky voices, but now helium is also helping people ... at the University of Alberta in Edmonton, Canada have ... oxygen allowed patients with chronic obstructive pulmonary disease (COPD) ... 245 per cent. COPD is a disease of the ...
Cached Biology News:UCI scientists reconstruct migration of avian flu virus 2Jefferson scientists find rabies-based vaccine could be effective against HIV 2Helium helps patients breathe easier 2
... evolutionarily conserved form of cell suicide, which ... central component of this process is a ... These enzymes participate in a series of ... pro-apoptotic signals and result in the cleavage ...
...
...
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Biology Products: